# Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

> **NCT02239900** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 143 (actual)

## Conditions studied

- Liver Cancer
- Lung Cancer

## Interventions

- **DRUG:** Ipilimumab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT02239900
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-26
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2020-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239900, "Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02239900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*